U.S. markets open in 8 hours 42 minutes
  • S&P Futures

    4,448.75
    -26.00 (-0.58%)
     
  • Dow Futures

    34,546.00
    -70.00 (-0.20%)
     
  • Nasdaq Futures

    14,677.00
    -164.00 (-1.11%)
     
  • Russell 2000 Futures

    2,016.30
    -4.90 (-0.24%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • Gold

    1,841.00
    -1.60 (-0.09%)
     
  • Silver

    24.50
    -0.21 (-0.85%)
     
  • EUR/USD

    1.1328
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.8330
    -1.8330 (-100.00%)
     
  • Vix

    25.59
    -23.85 (-100.00%)
     
  • GBP/USD

    1.3594
    -0.0006 (-0.04%)
     
  • USD/JPY

    113.8670
    -0.2330 (-0.20%)
     
  • BTC-USD

    38,843.59
    -3,015.40 (-7.20%)
     
  • CMC Crypto 200

    917.47
    -77.79 (-7.82%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,417.34
    -355.59 (-1.28%)
     

Down 30% in 6 Months: Is Tilray Still a Buy?

·4 min read
Down 30% in 6 Months: Is Tilray Still a Buy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TLRY

The Canadian cannabis company Tilray (NASDAQ: TLRY) hasn't been the best performer over the last six months, with its shares falling by more than 31% while the larger market rose by 14%. Is Tilray on track to be a strong performer in 2022, or is its tenuous positioning relative to the rapidly opening U.S. cannabis market going to be a problem? Right now, Tilray holds the largest share of the recreational and medicinal cannabis markets in Canada.